Lexicon Pharmaceuticals Announces Topline Clinical Data For LX9211; Data Shows LX9211 Was Well Tolerated And Met Primary Objectives, Demonstrating A 'Favorable' Safety And Tolerability Profile
Benzinga Newsdesk